Optimal healing and dual antiplatelet therapy duration for today's complex PCI: the Synergy™ stent
-
Keith G. Oldroyd
Dr. Oldroyd is Clinical Director of Cardiology at the new West of Scotland Regional Heart and Lung Centre based in the Golden Jubilee National Hospital in Glasgow. He was an investigator in both the SYNTAX and FAME trials. Dr Oldroyd trained in cardiology in Stoke-on-Trent and Glasgow and in interventional cardiology in Toronto.
-
Stephan Windecker
Prof. Windecker currently serves as chief of cardiology and director of invasive cardiology at the Swiss Cardiovascular Center Bern, Switzerland. He is also an executive board member of the Clinical Trials Unit (CTU) at Bern University Hospital and co-director of clinical research in the department of cardiovascular diseases.
Session details
- Chairpersons: Keith G. OLDROYD, Stephan WINDECKER
- Speakers: Keith G. OLDROYD, Javier ESCANED, Clemens VON BIRGELEN, Robert-Jan VAN GEUNS, Stephan WINDECKER
- Objectives:
To learn how durable and bioabsorbable polymers and stent design impact both early and late healing
To understand the current evidence when assessing ischaemic, bleeding and thrombotic risks for specific patient subsets
To learn how the Synergy™ stent is being used in complex patient subsets
Presentations
- Introduction and objectives (K.G. Oldroyd)
- Early and late healing: risk of bleeding, stent thrombosis and neoatherosclerosis in complex PCI today (J. Escaned) — 6min30
- Multivessel and diabetes mellitus (C. Von Birgelen) — 24min57
- Left main (R.J. Van Geuns) — 47min00
- Take-home message (S. Windecker) — 1h02min